Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia

Dasatinib, a tyrosine kinase inhibitor, is commonly used in the treatment of chronic myelogenous leukemia. A rare side effect is peripheral neuropathy. A 54-year-old woman experienced gradually accelerated dysesthesia and hypoesthesia in her extremities, 2 months following treatment with dasatinib....

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Hiroyasu, Taji, Hirofumi, Yamada, Kentaro, Iriyama, Chisako, Saito, Touko, Kato, Harumi, Yanada, Masamitsu, Yamamoto, Kazuhito, Matsukawa, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644482/
https://www.ncbi.nlm.nih.gov/pubmed/32611965
http://dx.doi.org/10.2169/internalmedicine.4824-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644482/
https://www.ncbi.nlm.nih.gov/pubmed/32611965
http://dx.doi.org/10.2169/internalmedicine.4824-20

Ejemplares similares